The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | Myelosuppression related to gilteritinib treatment in AML & impact on clinical trial design
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, briefly comments on some of the results from a trial evaluating the addition of gilteritinib to conventional intensive chemotherapy in patients with acute myeloid leukemia (AML). Dr Levis explains that gilteritinib treatment was associated with high rates of myelosuppression, which should be considered when designing clinical trials assessing gilteritinib in AML. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
